Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease

Annals of Surgery

Volumn 258, Issue 1, 2013, Pages 82-88

  Gibson, Michael K ^a   Zaidi, Ali H ^a,b   Davison, Jon M ^a   Sanz, Alejandro F ^a   Hough, Bruce ^a   Komatsu, Yoshihiro ^b   Kosovec, Juliann E ^b   Bhatt, Astha ^a   Malhotra, Usha ^d   Foxwell, Tyler ^a   Rotoloni, Christina L ^b   Hoppo, Toshitaka ^c   Jobe, Blair A ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ALLEGHENY HEALTH NETWORK   (United States)

^c WESTERN PENNSYLVANIA HOSPITAL   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Animal model; Chemoprevention; Esophageal cancer; Novel agent

Indexed keywords

BMS 833923; CASPASE 3; KI 67 ANTIGEN; SMOOTHENED PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; CANCER MORTALITY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG HALF LIFE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOJEJUNOSTOMY; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK REDUCTION; STEADY STATE; SURGICAL MORTALITY; THERAPY EFFECT; TREATMENT DURATION; WEIGHT REDUCTION;

ADENOCARCINOMA; ANIMALS; BARRETT ESOPHAGUS; BENZAMIDES; CASPASE 3; DISEASE MODELS, ANIMAL; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; HEDGEHOG PROTEINS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER;

EID: 84879083004     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318270500d     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Yoon HH, Gibson MK. Combined-modality therapy for esophageal and gastroesophageal junction cancers. Curr Oncol Rep. 2007;9:184-192. Epub 2007/04/14.
3. Paulson TG, Reid BJ. Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell. 2004;6:11-16.
4. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
5. Bonde P, Sui G, Dhara S, et al. Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model. J Thorac Cardiovasc Surg. 2007;133:763-769.
6. Oh DS, De Meester SR, Dunst CM, et al. Validation of a rodent model of Barrett's esophagus using quantitative gene expression profiling. Surg Endosc. 2009;23:1346-1352.
7. Lees C, Howie S, Sartor RB, et al. The hedgehog signalling pathway in the gastrointestinal tract: implications for development, homeostasis, and disease. Gastroenterology. 2005;129:1696-1710.
8. Roberts DJ, Johnson RL, Burke AC, et al. Sonic hedgehog is an endodermal signal inducing Bmp-4 and Hox genes during induction and regionalization of the chick hindgut. Development. 1995;121:3163-3174.
9. Sukegawa A, Narita T, Kameda T, et al. The concentric structure of the developing gut is regulated by Sonic hedgehog derived from endodermal epithelium. Development. 2000;127:1971-1980.
10. Sui G, Bonde P, Dhara S, et al. Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model. J Surg Res. 2006;134:1-9.
11. Ma X, Sheng T, Zhang Y, et al. Hedgehog signaling is activated in subsets of esophageal cancers. Int J Cancer. 2006;118:139-148.
12. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425:846-851.
13. Peukert S, Miller-Moslin K. Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. Chem Med Chem. 2010;5:500-512.
14. Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology. 2002;122:1101-1112.
15. Miwa K, Sahara H, Segawa M, et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer. 1996;67:269-274.
16. Miyashita T, Shah FA, Marti G, et al. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting. J Gastrointest Surg. 2008;12:2-7; discussion 2-9.
17. Cronin J, McAdam E, Danikas A, et al. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Am J Gastroenterol. 2011;106:46-56.
18. Soria JC, Jang SJ, Khuri FR, et al. Overexpression of cyclin B1 in earlystage non-small cell lung cancer and its clinical implication. Cancer Res. 2000;60:4000-4004.
19. Miyashita T, Shah FA, Marti GP, et al. Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical rat model. Dig Dis Sci. 2011;56:1309-1314.
20. Yamashita Y, Homma K, Kako N, et al. Effect of duodenal components of the refluxate on development of esophageal neoplasia in rats. J Gastrointest Surg. 1998;2:350-355.
21. Yang L, Bian Y, Huang S, et al. Identification of signature genes for detecting hedgehog pathway activation in esophageal cancer. Pathol Oncol Res. 2011;17:387-391.
22. Gupta S, Takebe N, Lorusso P. Targeting the Hedgehog pathway in cancer. Ther Adv Med Oncol. 2010;2:237-250.
23. Kiesslich T, Neureiter D. Advances in targeting the Hedgehog signaling pathway in cancer therapy. Expert Opini Ther Targets. 2012;16:151-156.
24. Wang DH, Clemons NJ, Miyashita T, et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology. 2010;138:1810-1822.
25. Jankowski JA, Harrison RF, Perry I, et al. Barrett's metaplasia. Lancet. 2000;356:2079-2085.
26. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
27. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002;2:331-341.
28. Ng JM, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev. 2011;11:493-501.
29. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
30. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550. Epub 2006/12/15.
31. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
32. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
33. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-1127.
34. Reid BJ, Li X, Galipeau PC, et al. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev. 2010;10:87-101. Epub 2010/01/23. doi: nrc2773 [pii] 10.1038/nrc2773. PubMed PMID: 20094044; PubMed Central PMCID: PMC2879265.
35. Kleinberg L, Gibson MK, Forastiere AA. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nat Clin Pract Oncol. 2007;4:282-294.
36. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.